Pri-Med in Partnership with the American College of Cardiology

New LIVE CME programs focused on the assessment and management of cardiovascular risk.		Curriculum Developed by Program Course Chairs: Roger Blumenthal, MD, FACC Johns Hopkins University, Baltimore, MD   Patrick T. O'Gara, MD, FACC Harvard Medical School; Brigham and Women's Hospital, Cardiovascular Division, Boston, MA For more in-depth CV information visit:
Heart disease remains the leading cause of death worldwide, and in the U.S. the majority of patients’ modifiable cardiometabolic risk factors are not being managed or treated to goal by their physicians: Two thirds of patients with hypertension are not managed to JNC targets2 Less than one half of patients with diabetes meet ADA target AIC goals3 Nearly 60% of patients being treated for dyslipidemia are not reaching NCEP target LDL-C goals1 Less than 40% of smokers receive counseling about smoking cession at routine office visits4
1 American Heart Association www.amheart.org 2 Qureshi AI et al. Med Sci Monit. 2006;11:403 409. 3 Centers for Disease Control and Prevention. www.cdc.org 4 Thorndike AN, et al. JAMA. 1998; 279:604–608.

Pri-Med and the American College of Cardiology have partnered together to bring you the latest, most relevant knowledge on cardiovascular risk management in this new national CME program.  Under the direction of ACC course chairs, Drs. Blumenthal and O’Gara, this program provides primary care clinicians with timely, real world information that can immediately be used when assessing and managing patients at risk for cardiovascular events.

Program Objectives

Attend this continuing medical education activity and you will be able to:

• List at least five key tenets to mitigating risk of cardiovascular disease for patients who present in the primary care setting.
• Outline the role of the primary care clinician in the prevention of secondary cardiovascular events in patients who are post-MI or post-stroke.
• List at least three key strategies for preventing CV events in patients with Type 2 diabetes.
• Outline short- and long-term considerations for antithrombotic therapy in a patient who has had a recent MI.
• Compare pharmacologic and non-pharmacologic strategies available for the treatment of tobacco dependence.
• Employ the NCEP ATP III guidelines in the evaluation and management of dyslipidemia, and outline strategies to facilitate the achievement of target lipids goals.
• List five primary considerations in the selection of antihypertensive therapies.